VERDOT®, a leader in downstream bioprocessing technologies, has announced its latest milestone with the acquisition of 11,000 square meters (2.7 acres) of land in the Biopole Clermont-Limagne Life Science Technology Park in Riom, France. This site will host a new 4200 square-meter (45,000 square-foot) headquarters and manufacturing facility, consolidating the company’s two existing locations. Construction is set to begin in early 2025, with an anticipated opening in early 2026.
Founded in 1950 and headquartered in Riom, VERDOT specializes in innovative purification solutions for the biopharmaceutical industry. The company’s expertise includes chromatography columns and tangential flow filtration (TFF) systems, which are essential for the purification, separation, and concentration of biomolecules such as monoclonal antibodies, vaccines, and mRNA-based therapeutics.
The new facility will serve as a Center of Excellence for bioprocessing manufacturing, research, and development, incorporating an advanced applications laboratory. By centralizing operations, VERDOT aims to improve engineering and R&D efficiencies, enhancing its capabilities to meet the global demand for cutting-edge biopharmaceutical purification technologies.
CEO Charles Ruban expressed excitement about the expansion: “The new VERDOT facility will add significant manufacturing capacity, allowing us to reduce lead times for tailored and standard purification technologies. The consolidation of our facilities will drive innovation and operational efficiency, while further reducing our carbon footprint.”
The new headquarters will offer 150% additional manufacturing capacity, create 50-75 new jobs in the local area, and integrate sustainable energy solutions. Designed to be energy-efficient and self-sufficient, it will feature water recycling systems and meet stringent environmental and regulatory standards. This aligns with VERDOT’s decarbonization strategy, which the company has been committed to for over a decade.
VERDOT serves a diverse customer base, including research and development, early-stage biotech firms, and contract development and manufacturing organizations (CDMOs), empowering them to accelerate the time-to-market of groundbreaking and cost-effective therapies.